On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 ﾵg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 ﾵg booster dose of mRNA-1273 in all participants regardless of prior infection. Superior performance against Omicron BA.1 was also durable, with higher antibody titers sustained through three months.

In addition, mRNA-1273.214 demonstrated significantly higher neutralizing antibody responses against Omicron BA.4/BA.5 compared to mRNA-1273 28 days after administration, as previously reported. Potent responses were also seen against Omicron BA.2.75 28 days after administration, suggesting that the bivalent booster elicits broad cross-neutralization against Omicron variants.